SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023

Juan Manuel Carreño, Abram L. Wagner, Brian Monahan, Gagandeep Singh, Daniel Floda, Ana S. Gonzalez-Reiche, Johnstone Tcheou, Ariel Raskin, Dominika Bielak, Sara Morris, Miriam Fried, Temima Yellin, Leeba Sullivan, Emilia Mia Sordillo (), Aubree Gordon (), Harm Bakel (), Viviana Simon () and Florian Krammer ()
Additional contact information
Juan Manuel Carreño: Icahn School of Medicine at Mount Sinai
Abram L. Wagner: University of Michigan
Brian Monahan: Icahn School of Medicine at Mount Sinai
Gagandeep Singh: Icahn School of Medicine at Mount Sinai
Daniel Floda: ISMMS
Ana S. Gonzalez-Reiche: ISMMS
Johnstone Tcheou: Icahn School of Medicine at Mount Sinai
Ariel Raskin: Icahn School of Medicine at Mount Sinai
Dominika Bielak: Icahn School of Medicine at Mount Sinai
Sara Morris: Icahn School of Medicine at Mount Sinai
Miriam Fried: Icahn School of Medicine at Mount Sinai
Temima Yellin: Icahn School of Medicine at Mount Sinai
Leeba Sullivan: Icahn School of Medicine at Mount Sinai
Emilia Mia Sordillo: Icahn School of Medicine at Mount Sinai
Aubree Gordon: University of Michigan
Harm Bakel: Icahn School of Medicine at Mount Sinai
Viviana Simon: Icahn School of Medicine at Mount Sinai
Florian Krammer: Icahn School of Medicine at Mount Sinai

Nature Communications, 2024, vol. 15, issue 1, 1-10

Abstract: Abstract Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-50052-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50052-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-50052-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().